Findings

What do systematic reviews say?

2,121 questions · 2,186 findings · 242 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 493 · 22.6%GRADE not reported 158 · 7.2%Very low 600 · 27.4%Low 474 · 21.7%Moderate 364 · 16.7%High 97 · 4.4%

Topical quinolone vs quinolones

Hearing · people (of any age) with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical quinolone vs quinolones

Serious complications · people (of any age) with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical quinolone vs quinolones

Suspected ototoxicity · people (of any age) with CSOM

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 265 participants
Very low

Topical quinolone vs intramuscular gentamicin

Resolution of ear discharge ‐ measured at 1 to 2 weeks · adults with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical quinolone vs intramuscular gentamicin

Resolution of ear discharge ‐ measured after 4 weeks · adults with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ AZLI vs placebo

FEV1 % predicted: relative change from baseline · adults and children with CF

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 99 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Time to next exacerbation · adults and children with CF

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Participants hospitalised for respiratory exacerbation · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 0.88 [0.53, 1.45]
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Adverse events (AEs) (1 or more events) · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 1.08 [0.98, 1.19]
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

All‐cause mortality · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 5.41 [0.27, 109.87]
1 study · 100 participants
Moderate

Cefazolin plus amikacin vs vancomycin plus amikacin

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.7 [0.29, 1.66]
1 study · 109 participants
Very low

Meropenem vs usual care

Serious adverse events maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 1.54 [0.9, 2.66]
1 study · 271 participants
Very low

Meropenem vs usual care

Neurological developmental impairment maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes neurological developmental impairment maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.87 [0.51, 1.48]
1 study · 271 participants
Very low

Meropenem vs usual care

Necrotising enterocolitis maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes necrotising enterocolitis maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.68 [0.33, 1.42]
1 study · 271 participants
Very low

Vancomycin plus gentamicin vs vancomycin plus aztreonam

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.65 [0.2, 2.13]
1 study · 81 participants
Very low

Vancomycin plus gentamicin vs vancomycin plus aztreonam

Serious adverse events maximum · newborns with late‐onset sepsis

It is very uncertain whether vancomycin plus gentamicin changes serious adverse events maximum compared with vancomycin plus aztreonam (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.65 [0.2, 2.13]
1 study · 81 participants
Very low

Vancomycin plus gentamicin vs vancomycin plus aztreonam

Necrotising enterocolitis maximum · newborns with late‐onset sepsis

It is very uncertain whether vancomycin plus gentamicin changes necrotising enterocolitis maximum compared with vancomycin plus aztreonam (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 12.69 [0.74, 218.09]
1 study · 81 participants
Very low

Cefazolin plus amikacin vs vancomycin plus amikacin

Serious adverse events maximum · newborns with late‐onset sepsis

It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.7 [0.29, 1.66]
1 study · 109 participants
Very low

Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.82]
1 study · 28 participants
Very low

Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin

Serious adverse events maximum · newborns with late‐onset sepsis

It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with flucloxacillin and gentamicin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.82]
1 study · 28 participants
Very low